Gene Editing Market Size Expected to Reach USD 29.93 Bn by 2032

The global gene editing market size is estimated to reach around USD 29.93 billion by 2032, increasing from USD 6.94 billion in 2022.

The global gene editing market size accounted for USD 8.04 billion in 2023 and is growing at a healthy CAGR of 15.73% from 2023 to 2032.

Key Takeaways:

• North America has generated more than 49% of revenue share in 2022.
• By Product & Services, the reagents & consumables segment is expected to lead the market during the forecast period.
• By Technology, the CRISPR segment is expected to witness a significant growth throughout the forecast period.
• By Application, the cell line engineering segment is anticipated to dominate the gene editing market during the predicted market.
• By End-user, pharmaceuticals and biotechnology companies segment is expected to sustain its dominance in the market.

Gene editing, also known as genome gene editing, is a genetic engineering method that entails making specific changes to the DNA sequence of a living organism. These alterations can involve inserting, deleting, modifying, or replacing genetic material within the targeted genome sequence. In simpler terms, gene editing allows scientists to precisely adjust an organism’s genetic code. The market embraces a spectrum of techniques for altering the DNA within an organism’s genome, encompassing activities like adding, removing, or modifying specific segments of DNA.

Gene editing technology is the foremost method for dissecting gene function, delving into the root causes of hereditary disorders, pinpointing novel targets for gene therapy, cultivating diverse crop varieties, and undertaking multifaceted tasks within the life sciences realm. This unparalleled efficiency stems from the swift advancement of gene editing technology. The discovery and honing of contemporary gene-editing techniques have notably streamlined the manipulation of production hosts.

The gene editing market is dominant in North America. Its advanced healthcare infrastructure, widespread adoption of cutting-edge technologies by animal genetic companies, and a burgeoning number of laboratories drive it. Major market players in the United States and substantial investments in research and development contribute significantly to the region’s market leadership. In contrast, the Asia Pacific region is poised for rapid growth, fueled by increased government funding in biotechnology for improved disease treatment, rising disposable incomes, a gradual uptake of technology, a high demand for animal proteins, and a regulatory environment characterized by some disorganization across and within nations.

The Full Study is Readily Available | Download the Sample Pages of this Report@ https://www.precedenceresearch.com/sample/3239

Growth Factors

• Technological advancements present opportunities for treating genetic issues and developing cutting-edge medicines. In agriculture, gene editing is employed to enhance crop qualities, addressing concerns related to disease resistance, improved nutrition, and extended shelf life. This contributes to increased crop yields and improved food security.
• The market’s growth is driven by supportive government guidelines in synthetic biology, increasing demand for synthesized genes and cells, and significant investments from government entities and major players in the field. Furthermore, advancements in gene therapy and molecular biology contribute to market expansion, particularly developing and applying state-of-the-art gene editing techniques. Additionally, the progress in genome engineering, the availability of user-friendly gene therapy systems, and gene therapy’s capacity to facilitate swift genome-wide examination of gene function are vital factors aiding market growth throughout the forecast period.
• The gene editing market is witnessing growth due to the increasing prevalence of cancer and genetic disorders, a rising preference for personalized medicine augmented funding from private and public sectors, and rapid advancements in sequencing and genome editing technologies. For instance, the Somatic Cell Genome Editing (SCGE) Program at the National Institutes of Health (NIH) has recently granted 24 additional awards to researchers in the United States and Canada, totaling USD 89 million in advance genome editing grants over the next four years, as reported by the National Center for Advancing Translational Sciences in June 2022.
• Collaborations play a significant role in the market’s growth. For instance, a few years back, Eli Lilly collaborated with Precision BioSciences to explore and develop potential in vivo therapies for genetic disorders using the ARCUS platform. This collaboration has the potential to generate approximately USD 2.7 billion for Precision BioSciences, a Durham, NC-based developer of therapies based on genome editing and ‘off-the-shelf’ CAR T immunotherapies. Therefore, such collaborations are poised to contribute to the market’s expansion shortly.

Personalized your customization here: https://www.precedenceresearch.com/customization/3239

Red Biotechnology Market Scope

We’ve prepared a service to help you write your own Go-To-Market strategy.

Click to Unlock Your GTM Strategy for the Gene Editing Market

Market Potential

Research studies on CRISPR technology contribute significantly to the market’s growth. For instance, the ‘CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia’ study was published in the New England Journal of Medicine in January 2021. This research explores the application of CRISPR-Cas9-based gene editing to treat two inherited diseases: TDT (β-Thalassemia) and SCD (Sickle Cell Disease). In the 12 months following the administration of CTX001, both patients experienced substantial and sustained increases in fetal haemoglobin levels, exceeding 99% pancellularity. This indicates a promising application of CRISPR technology in addressing Sickle Cell Disease and β-Thalassemia, leading to increased demand over the forecast period.

One important factor propelling market expansion is the introduction of new products. The Drug Controller General of India granted regulatory approval for the commercial introduction of the Tata CRISPR FELUDA test, powered by CSIR-IGIB, in September 2020, in accordance with ICMR criteria. This test uses an indigenously developed CRISPR technique to detect the genetic sequence of the SARS-CoV-2 virus, and it meets high-quality benchmarks with 96% sensitivity and 98% specificity for detecting the novel coronavirus. The genome-editing technique CRISPR is essential for diagnosing diseases.

Browse More Insights:

DNA Diagnostics Market: The global DNA diagnostics market size was reached at USD 12.46 billion in 2022 and it is projected to hit around USD 20.1 billion by 2032, registering a CAGR of 4.9% from 2023 to 2032.

DNA Sequencing Market: The global DNA sequencing market size is expected to be worth around US$ 37.99 billion by 2032 from US$ 9.69 bn in 2022, with a compound annual growth rate (CAGR) of 14.7% from 2023 to 2032.

Cancer Gene Therapy Market: The global cancer gene therapy market size was estimated at USD 2.37 billion in 2022 and is projected to hit around USD 15.2 billion by 2032, poised to grow at a CAGR of 20.42% 2023 to 2032.

Cell and Gene Therapy Clinical Trials Market: The global cell and gene therapy clinical trials market size reached USD 10.05 billion in 2022 and is expected to hit around USD 40.98 billion by 2032, growing at a CAGR of 15.09% from 2023 to 2032.

Cell and Gene Therapy Market: The global cell and gene therapy market size was exhibited at USD 15.46 billion in 2022 and is projected to hit around USD 82.24 billion by 2032, growing at a CAGR of 18.3% from 2023 to 2032.

Cell Culture Market: The global cell culture market size was accounted at US$ 24.19 billion in 2022 and it is expected to surpass around US$ 63.60 billion by 2032 with a registered CAGR of 10.20% during the forecast period 2023 to 2032.

Gene Therapy Market: The global gene therapy market size was valued at US$ 6.50 billion in 2022 and is expected to reach over US$ 38.76 billion by 2032, poised to grow at a registered CAGR of 19.60% from 2023 to 2032.

Plasmid DNA Manufacturing Market: The global plasmid DNA manufacturing market size was valued at US$ 446.13 million in 2022 and is expected to reach US$ 2,156.58 million by 2030, poised to grow at a CAGR of 21.7% from 2022 to 2030.

Viral Vectors & Plasmid DNA Manufacturing Market: The global viral vectors & plasmid DNA manufacturing market size was estimated at USD 1,237.45 million in 2022 and it is expected to hit around USD 5,989.21 million by 2032 and expanding growth at a noteworthy CAGR of 16.8% from 2023 to 2032.
Red Biotechnology Market: The global red biotechnology market size was valued at USD 365.25 billion in 2022 and is expected to reach over USD 618.64 billion by 2032, growing at CAGR of around 5.41% from 2023 to 2032.

Industry Spotlight

• In May 2023, technology innovation firm New Biologix SA emerged, unveiling a groundbreaking platform for creating cell lines essential in producing genes and cell therapies. Using recombinant adeno-associated viral vectors, their DNA-based technology addresses significant manufacturing challenges in advanced therapy medical products (ATMPs).
• In June 2023, pharmaceutical company Laurus Labs Ltd announced signing a Memorandum of Agreement (MoA) with the Indian Institute of Technology Kanpur (IITK). The agreement involves acquiring the rights to novel gene therapy assets that utilise Adeno Adeno-associated virus (AAV) vectors and bringing them to the market.
• In February 2022, Integrated DNA Technologies introduced Alt-R HDR Donor Blocks, an enhanced solution to improve homology-directed repair (HDR) rates. This innovation is the latest addition to IDT’s comprehensive Alt-R CRISPR genome editing solutions portfolio.
• In February 2022, Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. shared positive interim data from an ongoing Phase I clinical study of their primary in vivo genome editing candidate, NTLA-2001, which is an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis.

Company Synopsis

Creative Biogene

Creative Biogene serves as the primary global provider of client services and solutions for scientific research, dedicating itself to the development, manufacturing, and purification of recombinant adenoviruses, adeno-associated virus (AAV), and lentivirus for gene delivery and gene knockdown. Biogen Inc. (NASDAQ: BIIB) has appointed Christopher A. Viehbacher as the new President and Chief Executive Officer, as well as a member of the Board of Directors, effective November 14. Viehbacher takes over from Michel Vounatsos, who has led the company since 2017.

Synthego

Synthego is a leading provider of genome engineering solutions, offering a product lineup that includes software and synthetic RNA kits specifically crafted for CRISPR genome editing and research. On August 24, 2023, Synthego, a prominent provider of genome editing solutions for streamlined advancements from discovery to clinical applications, and bit. Bio, a company focused on programming human cells for innovative cures, declared a strategic partnership. This collaboration aims to establish a platform that integrates synthetic circuitry into cells for therapeutic purposes.

Key Market Players:

• Beren Therapeutics
• Agilent Technologies
• Creative Biogene
• Thermo Fisher-Scientific
• Synthego
• Integrated DNA Technologie
• Bean Therapeutics
• Intellia Therapeutics
• Lonza
• Horizon Discovery Group plc.
• Tecan Life-Sciences
• Bluebird Bio

Key Market Segments:

By Product & Services

• Reagents & Consumables
• Software & Systems
• Services
  

By Technology

• Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
• Transcription Activator-Like Effector Nuclease (TALEN)
• Zinc Finger Nuclease (ZFN)
• Antisense
• Other technologies
  

By Application

• Cell Line Engineering
• Genetic Engineering
• Drug Discovery & Development
• Other Applications
  

By End-user

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
  

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/3239

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 650 460 3308

Unlocking Market Insights through Data Excellence

The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

About Us

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.
Web: https://www.precedenceresearch.com

Our Blogs:

https://www.towardshealthcare.com

https://www.towardspackaging.com
For Latest Update Follow Us:
Linkedin | Facebook | Twitter